Join our LinkedIn PATENTSCOPE users Community Group
Feedback
Settings

Settings

Goto Application

200,050 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K38/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 20,005
1.WO/2024/092717PROTEIN DERIVED FROM FIBRONECTIN TYPE III DOMAIN, AND USE THEREOF
WO - 10.05.2024
Int.Class C07K 14/78
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin (CIG)
 Appl.No PCT/CN2022/129857 Applicant CHUANG, Woei Jer Inventor CHUANG, Woei Jer
Provided is a protein derived from a fibronectin type III domain, and the use thereof. The protein comprises the 10th human fibronectin type III domain, and comprises a first mutation where one amino acid site is substituted with one cysteine and a second mutation where another amino acid site is substituted with another cysteine. The first mutation and the second mutation occur in regions other than the loop FG of the 10th human fibronectin type III domain, whereby the cysteine after the substitution in the first mutation and the cysteine after the substitution in the second mutation form a disulfide bond.
2.WO/2024/093752NOVEL ANTIMICROBIAL PEPTIDE AND PHARMACEUTICAL COMPOSITION THEREOF
WO - 10.05.2024
Int.Class C07K 7/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04Linear peptides containing only normal peptide links
08having 12 to 20 amino acids
 Appl.No PCT/CN2023/126448 Applicant QINGDAO SENSHENG BIOPHARMACEUTICAL TECHNOLOGY CO., LTD Inventor SU, Feng
Provided are an antimicrobial peptide that is safe, has high stability, a good antimicrobial effect, and a shorter sequence, as well as pharmaceutical composition thereof, which can be used for treating and relieving rosacea, adolescent acne, atopic dermatitis, genital warts, vulval intraepithelial neoplasia, inflammatory responses, inflammatory response syndrome, etc. The antimicrobial polypeptide comprises the amino acid sequence Ac-SRMKKWAKIIEKWRKWH-NH2.
3.WO/2024/094217METHOD FOR PROMOTING PATHOLOGICAL TDP-43 PROTEIN DEGRADATION, AND DRUG
WO - 10.05.2024
Int.Class A61K 38/49
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
43Enzymes; Proenzymes; Derivatives thereof
46Hydrolases (3)
48acting on peptide bonds (3.4)
49Urokinase; Tissue plasminogen activator
 Appl.No PCT/CN2023/130019 Applicant TALENGEN INTERNATIONAL LIMITED Inventor LI, Jinan
The present application relates to a method of promoting pathological TDP-43 protein degradation, which comprises administering to a subject a therapeutically effective amount of one or more compounds among: a plasminogen activation pathway component, a componud capable of directly activating plasminogen or indirectly activating plasminogen by means of activating a plasminogen activation pathway upstream component, a compound simulating the activity of plasminogen or plasmin, a compound capable of upregulating plasminogen or plasminogen activator expression, a plasminogen analogue, a plasmin analogue, a tPA or uPA analogue, and a fibrinolysis inhibitor antagonist. The present application also relates to a drug for promoting pathological TDP-43 protein degradation and a use thereof.
4.WO/2024/097772COMPOSITIONS AND METHODS FOR TREATMENT OF FRIEDREICH'S ATAXIA
WO - 10.05.2024
Int.Class A61K 31/7088
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
 Appl.No PCT/US2023/078373 Applicant LACERTA THERAPEUTICS, INC. Inventor HAMM, Matthew
The present application provides compositions for treatment of Friedreich's Ataxia (FA). These include, but are not limited to, nucleic acid constructs and recombinant AAV7 vectors comprising a human frataxin 5' untranslated region (5'UTR FXN) and a human frataxin (FXN).
5.WO/2024/094216METHOD AND DRUG FOR PROMOTING REMOVAL OF PATHOLOGICAL PROTEINS BY UBIQUITIN PROTEASOME SYSTEM AND AUTOPHAGY LYSOSOME SYSTEM
WO - 10.05.2024
Int.Class A61K 38/48
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
43Enzymes; Proenzymes; Derivatives thereof
46Hydrolases (3)
48acting on peptide bonds (3.4)
 Appl.No PCT/CN2023/130018 Applicant TALENGEN INTERNATIONAL LIMITED Inventor LI, Jinan
A method for regulating and optimizing a ubiquitin proteasome system and/or an autophagy lysosome system in order to promote the degradation of intracellular and extracellular pathological proteins; a drug for promoting the degradation of intracellular and extracellular pathological proteins; and the use thereof.
6.WO/2024/097051IMMUNOTHERAPY COMPOSITIONS AND METHODS OF USE
WO - 10.05.2024
Int.Class A61K 35/13
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
13Tumour cells, irrespective of tissue of origin
 Appl.No PCT/US2023/035802 Applicant PYROJAS INC. Inventor BAGATI, Archis
The disclosure leverages the therapeutic potential of autologous and allogenic cells, particularly cancer cells and T cells, which have been genetically modified or contacted with specific recombinant proteins, peptides, or nucleic acids encoding these entities. These modified cells are primed to elicit various immune and inflammatory responses in the tumor microenvironment, thereby bolstering the body's natural ability to recognize and destroy tumor cells.
7.WO/2024/097696MIXED RELEASE PROFILE POLYMER MICROSPHERE FORMULATIONS COMPRISING OCTREOTIDE AND METHODS FOR MAKING AND USING THE SAME
WO - 10.05.2024
Int.Class A61K 9/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders
16Agglomerates; Granulates; Microbeadlets
 Appl.No PCT/US2023/078271 Applicant OAKWOOD LABORATORIES, LLC Inventor VILLAROSA, Audrey
Mixed release profiled polymer microsphere formulations comprising octreotide are provided. In one aspect, the microsphere formulations are characterized in that octreotide is released in vivo in humans over a period of about 60 days. Methods for making and using the formulations are also provided.
8.WO/2024/098071THERAPEUTIC REGIMENS AND METHODS FOR TREATMENT OF CARDIOVASCULAR RISK FACTORS USING A GLP-1R AND GCGR AGONIST
WO - 10.05.2024
Int.Class A61K 38/26
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
22Hormones
26Glucagons
 Appl.No PCT/US2023/078850 Applicant SPITFIRE PHARMA LLC Inventor SUSCHAK III, John, Joseph
This disclosure relates to the once weekly dosing regimen of a dual GLP-1R and GCGR agonist, formulations, and methods of using the same for treatment of cardiovascular disease/disorder and/or reducing risk factors thereof by inducing reduction of pathogenic serum lipid mediators in a human being, wherein the human may or may not have other comorbidities such as obesity and/or type 2 diabetes. The dual GLP-1R and GCGR agonist includes the peptide product of SEQ ID NO. 1 (pemvidutide).
9.WO/2024/094237INSULIN DERIVATIVES
WO - 10.05.2024
Int.Class A61K 38/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
22Hormones
28Insulins
 Appl.No PCT/CZ2023/050072 Applicant USTAV ORGANICKE CHEMIE A BIOCHEMIE AKADEMIE VED CR, V. V. I. Inventor JIRACEK, Jiri
Novel derivatives of human insulin are described that have binding affinities for the IGF-1 receptor surprisingly comparable to human IGF-1, while having higher affinities for both isoforms of the insulin receptor than human insulin. The novel insulin derivatives have D-histidine or glycine at position B24, the B chain has glycine at the C-terminus at position B31 and tyrosine at position B32, and glutamic or aspartic acid at position B10. The derivatives of the invention can be used particularly for growth and proliferation stimulation in cell cultures or for treatment of neurological disorders as of Alzheimer's disease, Huntington's and Parkinson's diseases, a cognitive loss or symptoms of syndromic autism, since one derivative could mediate both insulin and IGF-1 function.
10.WO/2024/094597METHOD OF PREPARATION OF AMYLOIDOGENIC PROTEIN AGGREGATES AND USES THEREOF
WO - 10.05.2024
Int.Class C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
 Appl.No PCT/EP2023/080193 Applicant ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) Inventor LIMORENKO, Galina
The invention relates to methods for the preparation of method of preparation of Tau aggregates, including fibrils, fibrillar species, soluble and insoluble oligomeric species, new Tau aggregates and uses thereof. The invention further relates to the uses of the method of preparation of the so generated Tau aggregates for the identification and screening of modulators of Tau aggregation.
# -